XOMA - XOMA Royalty Revenue Growth YoY (Last 12 Months)

XOMA Royalty relies on antibody licensing and high-tech IT analysis of bio-assets. Stability is ensured by the non-cyclical nature of the pharmaceutical market, where demand remains independent of economic conditions. Revenues are based on the success of partners, which eliminates internal R&D costs. Relative revenue growth over the last four quarters compared to last year visualizes the sales trajectory, and the 13.00 mark shows the current state of this metric.
Summary analytical data breakdowns for XOMA Royalty (XOMA)

XOMA Royalty accumulates profit by purchasing rights to future revenues from third-party biopharmaceutical developments, completely eliminating the costs of its own research. The dynamics of these inflows are reflected in the annual sales growth rate over a 12-month period, which calculates the percentage change in revenue over a rolling year, allowing the investor to distinguish organic growth of the royalty portfolio from one-off transactions.